207 Terlipressin influence in spontaneous bacterial peritonitis

Chelarescu, O.; Chelarescu, D.; Stratan, I; Filip, Cristiana

doi:10.1016/s0168-8278(04)90207-3

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57 This regimen improved the hyper-dynamic circulation compared with ceftriaxone alone. There was a significant increase in SBP reversal and a reduction in mortality with terlipressin at 48 h. Therefore the use of a vasoconstrictor should be investigated as a potential alternative, or additive, to albumin in the prevention of renal impairment in SBP.…”

Section: Prevention and Treatment Of Acute Kidney Injury (Aki) In Infmentioning

confidence: 96%

Bacterial infections in end-stage liver disease: current challenges and future directions

Bajaj

O’Leary

Wong

et al. 2012

Gut

View full text Add to dashboard Cite

Section: Prevention and Treatment Of Acute Kidney Injury (Aki) In Infmentioning

confidence: 96%

Bacterial infections in end-stage liver disease: current challenges and future directions

Bajaj

O’Leary

Wong

et al. 2012

Gut

View full text Add to dashboard Cite

“…Two RCTs informed our recommendation regarding Terlipressin. In addition to the above study, Chelarescu et al (61) randomized 55 cirrhotic patients with SBP to cefotaxime or cefotaxime and terlipressin. The cefotaxime and terlipressin group had decreased mortality and increased resolution of SBP at 48 hours and 5 days as well as lower recurrence rates of SBP.…”

Section: Methodsmentioning

confidence: 99%

“…Furthermore, both studies were at high risk of bias secondary to small sample sizes and lack of concealment, blinding and description of randomization. Further, the study by Chelarescu et al (61) was only published in abstract form.…”

Section: Methodsmentioning

confidence: 99%

Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations

Nanchal

Subramanian

Alhazzani

et al. 2023

Critical Care Medicine

View full text Add to dashboard Cite

To develop evidence-based recommendations for clinicians caring for adults with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. DESIGN:The guideline panel comprised 27 members with expertise in aspects of care of the critically ill patient with liver failure or methodology. We adhered to the Society of Critical Care Medicine standard operating procedures manual and conflictof-interest policy. Teleconferences and electronic-based discussion among the panel, as well as within subgroups, served as an integral part of the guideline development. INTERVENTIONS:In part 2 of this guideline, the panel was divided into four subgroups: neurology, peri-transplant, infectious diseases, and gastrointestinal groups. We developed and selected Population, Intervention, Comparison, and Outcomes (PICO) questions according to importance to patients and practicing clinicians. For each PICO question, we conducted a systematic review and meta-analysis where applicable. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. We used the evidence to decision framework to facilitate recommendations formulation as strong or conditional. We followed strict criteria to formulate best practice statements. MEASUREMENTS AND MAIN RESULTS:We report 28 recommendations (from 31 PICO questions) on the management ALF and ACLF in the ICU. Overall, five were strong recommendations, 21 were conditional recommendations, two were best-practice statements, and we were unable to issue a recommendation for five questions due to insufficient evidence. CONCLUSIONS: Multidisciplinary, international experts formulated evidence-based recommendations for the management ALF and ACLF patients in the ICU, acknowledging that most recommendations were based on low quality and indirect evidence.

show abstract

“…Remarkably, many patients do not relapse when treatment is discontinued confirming the paradigm that HRS is a potentially reversible condition [29]. Terlipressin may also have a role in the prevention of renal failure in patients who develop SBP and may also be as effective as albumin infusion in the prevention of post-paracentesis circulatory dysfunction [37,38]. Despite the powerful pressor response to terlipressin, ischaemic side effects are rare and usually limited to transient abdominal cramping in 10% of individuals.…”

Section: Vasopressin Analoguesmentioning

confidence: 95%